Endometrial cancer after tamoxifen treatment: A descriptive study of 25 breast cancer patients who subsequently developed endometrial cancer

Anticancer Research

Volumn 16, Issue 5 B, 1996, Pages 3241-3246

  Peters Engl, Christian ^a   Medl, Michael ^a   Danmayr, Eberhard ^b   Mirau, Michael ^a   Alth, Gerhard ^b   Leodolter, Sepp ^a  

^a GENERAL HOSPITAL LINZ   (Austria)

^b LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

Breast; Endometrial cancer; Tamoxifen

Indexed keywords

TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER REGISTRY; CANCER STAGING; CLINICAL ARTICLE; DRUG INDUCED CANCER; ENDOMETRIUM CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; PROGNOSIS; TAMOXIFEN;

EID: 0029799804     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic. or immune therapy: 133 randomised trials involving 31000 recurrences and 24000 deaths among 75000 women. Lancet 339: 1-15,71-85, 1992.
2. Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh: Adjuvant tamoxifen in the management of operable breast cancer: The Scottish Trial. Lancet ii: 171-175, 1987.
3. Fisher B, Constantino J, Redmond C, Poisson R, Bowman D, Couture J, et al: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor- positive tumors. N Engl J Med 320: 479-484, 1989.
4. Love RR: Tamoxifen prophylaxis in breast cancer. Oncology (Willston Park) 6: 33-43, 1992.
5. Fisher B, Redmond C: New perspective on cancer of the contralateral breast: a marker for assessing tamoxifen as a preventing agent. J Natl Cancer Inst 83: 1278-1280, 1991.
6. Powles TJ: The case for clinical trials of tamoxifen for prevention of breast cancer. Lancet 340: 1145-1147, 1992.
7. Veronesi U, Costa A, Sacchini V, Luini A, Bonanni B, Veronesi P: Italian study on the chemoprevention of breast cancer with tamoxifen. Contracept Fertil Sex 23(4): 258-260, 1995.
8. Killackey MA, Hakes TB, Pierce VK: Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat Rep 69: 237-238, 1985.
9. Jordan VC: Tamoxifen and endometrial cancer. Lancet 2: 1019, 1988.
10. Hardell L: Tamoxifen as a risk factor for carcinoma of corpus uteri. Lancet 2: 563, 1988.
11. Fornander T, Rutqvist LE, Cedermark B, Glas U, Mattson A: Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1: 117-120, 1989.
12. Gusberg SB: Tamoxifen for breast cancer-assosiated endometrial cancer. Cancer 65: 1463-1464, 1990.
13. Atlante G, Pozzi M, Vincenzoni C, Vocaturo G: Four case reports presenting new acquisitions on the association between breast and endometrial carcinoma. Gynecol Oncol 37: 378-380, 1990.
14. Malfetano JH: Tamoxifen-associated endometrial carcinoma in postmenopausal breast cancer patients. Gynecol Oncol 39: 82-84, 1990.
15. Mathew A, Chabon AB, Kabakow B, Drucker M, Hirschmann RJ: Endometrial carcinoma in five patients with breast cancer on tamoxifen therapy. NY State J Med 90: 207-208, 1990.
16. Spinelli G, Bardazzi N, Citernesi A, Fontanarosa M, Curiel P: Endometrial carcinoma in tamoxifen-treated breast cancer patients. J Chemother 3: 276-270, 1991.
17. De Muylder X, Neven P, De Somer M, Van-Belle Y, Vanderick G, De Muylder E: Endometrial lesions in patients undergoing tamoxifen therapy. Int J Gynaecol Obstet 36: 127-130 1991.
18. Andersson M, Storm HH, Mouridsen HT: Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J Natl Cancer Inst 83: 1013-1017, 1991.
19. Andersson M, Storm HH, Mouridsen HT: Carcinogenic effects of adjuvant tamoxifen treatment and radiotherapy for early breast cancer. Acta Oncol 31: 259-263, 1992.
20. Seud MAF, Johnson J, Weed JC: Gynecologic tumors in tamoxifen-treated women with breast cancer. Obstet Gynecol 82(2): 165-169, 1993.
21. Van Leeuwen FE, Benraadt J, Coebergh JWW, Kiemeney LA, Gimbrere CH, Otter R, et al: Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 343: 448-452, 1994.
22. Boccardo F, Bruzzi P, Rugragotti A: Estrogen-like action of tamoxifen on vaginal epithelium in breast cancer patients. Oncology 38: 281-285, 1981.
23. Patterson JS: Clinical aspects and development of antiestrogen therapy: a review of the endocrine effects of tamoxifen in animals and man. J Endocrinol 89: 67-75, 1981.
24. Gottardis MM, Robinson SP, Satyaswaroop PG, Jordan VC: Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res 48: 812-815, 1988.
25. Nolvadex Adjuvant Trial Organization: Controlled trial of tamoxifen as a single agent in the management of early breast cancer. Br J Cancer 57: 608-611, 1988.
26. Riheiro G, Swindell R: The Christie hospital adjuvant tamoxifen trial - status at 10 years. Br J Cancer 57: 601-603, 1988.
27. Stewart H, Knight GM: Tamoxifen and the uterus and endometrium. Lancet 1: 375-376, 1989.
28. Neven P, DeMuylder X, VanBelle Y: Tamoxifen and the uterus and endometrium. Lancet 1: 375, 1989.
29. Nayfield SG, Karp JE, Ford LG, Dorr FA, Kramer BS: Potential role oftamoxifen in prevention of breast cancer. J Natl Cancer Inst 83: 1450-1459, 1991.
30. Kurman RJ. Blaustein's Pathology of the Female Genital Tract. 3rd ed. New York: Springer-Verlag, 1987.
31. American Joint Committee on Cancer. Handbook for Staging of Cancer. In: Manual for Staging of Cancer. 4th ed. Philadelphia: J B Lippincott Company, 1993.
32. Creasman WT: New gynecologic cancer staging. Obstet Gynecol 75: 287-288, 1990.
33. Fisher B, Constantino JP, Redmond CK, Fisher ER, Wickerham DL. Cronin WM: Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Adjuvant Breast and Bowel Project (NSAPB-14). J Natl Cancer Inst 86: 527-537, 1994.
34. Stewart HJ: The Scottish trial of adjuvant tamoxifen in node-negative breast cancer. Scottish Cancer Trials Breast Group. Monogr Natl Cancer Inst 11: 117-120, 1992.
35. Margriples U, Naftolin F, Schwartz PE, Carcangiu ML: High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Ocol 11: 485-490, 1993.
36. Fornander T, Hellstrom AC, Moberger B: Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer. J Cancer Inst 85(22): 1850-1855, 1993.
37. Barakat RR, Wong G, Curtin JP, Vlamis V, Hoskins WJ: Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic feature. Gynecol Oncol 55(2): 164-168, 1994.
38. Cohen I, Doron JD, Rosen JD, Shapira J, Cordoba M, Gilboa S, et al: Endometrial changes with tamoxifen: Comparison between tamoxifen-treated and nontreated asymptomatic, postmenopausal breast cancer patients. Gynecol Oncol 52(2): 185-190, 1994.
39. Kedar RP, Bourne TH, Powles TJ, Collins WP, Ashley SE, Cosgrove DO, et al. Effects of tamoxifen on uterus and ovaries of post-menopausal women in a randomised breast cancer prevention trial. Lancet 343: 1318-1321, 1994.